Science Advances publishes proteomics technology from Oblique Therapeutics AB
The company's Abiprot technology identifies antibody binding sites on native-state, disease-relevant proteins at high resolution. The platform has the potential to bring game-changing benefits to large populations of patients suffering from uncurable diseases.